Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

BACKGROUND: Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age. METHODS: A phase 1, dose-finding study and an ongoing phase 2–3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, Emmanuel B., Talaat, Kawsar R., Sabharwal, Charu, Gurtman, Alejandra, Lockhart, Stephen, Paulsen, Grant C., Barnett, Elizabeth D., Muñoz, Flor M., Maldonado, Yvonne, Pahud, Barbara A., Domachowske, Joseph B., Simões, Eric A.F., Sarwar, Uzma N., Kitchin, Nicholas, Cunliffe, Luke, Rojo, Pablo, Kuchar, Ernest, Rämet, Mika, Munjal, Iona, Perez, John L., Frenck, Robert W., Lagkadinou, Eleni, Swanson, Kena A., Ma, Hua, Xu, Xia, Koury, Kenneth, Mather, Susan, Belanger, Todd J., Cooper, David, Türeci, Özlem, Dormitzer, Philip R., Şahin, Uğur, Jansen, Kathrin U., Gruber, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609605/
https://www.ncbi.nlm.nih.gov/pubmed/34752019
http://dx.doi.org/10.1056/NEJMoa2116298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609605/
https://www.ncbi.nlm.nih.gov/pubmed/34752019
http://dx.doi.org/10.1056/NEJMoa2116298

Ejemplares similares